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Abstract
Introduction: Zostavax, a live attenuated vaccine, has been approved in the United States for use in older
individuals to reduce the risk and severity of herpes zoster (HZ), also known as shingles. The vaccine is
contraindicated in individuals taking anti-tumor necrosis factor alpha (anti-TNF) therapies or other biologics
commonly used to treat autoimmune diseases because of the safety concern that zoster vaccine may be
associated with a short-term HZ risk. The objective of the study was to examine the use, safety (short-term HZ risk
after vaccination), and effectiveness of zoster vaccine in individuals with rheumatoid arthritis, psoriasis, psoriatic
arthritis, ankylosing spondylitis, and/or inflammatory bowel diseases.
Methods: We conducted a cohort study of patients aged 50 years and older with rheumatoid arthritis,
psoriasis, psoriatic arthritis, ankylosing spondylitis, and/or inflammatory bowel diseases by using administrative
claims data from a nationwide health plan from January 1, 2005, to August 31, 2009. We examined the extent
to which zoster vaccine was used; assessed factors associated with vaccine use (Cox proportional hazards
regression); and compared the incidence rates of herpes zoster (HZ) between vaccinated and unvaccinated
patients.
Results: Among 44,115 patients with the autoimmune diseases, 551 (1.2%) received zoster vaccine, and 761
developed HZ. Zoster vaccine use increased continuously after approval in 2006. Younger and healthier patients,
those who had an HZ infection within the past 6 months, and those who were not using anti-TNF therapies were
more likely to receive the vaccine. Approximately 6% of vaccinated patients were using anti-TNF therapies at the
time of vaccination. The incidence rates of HZ were similar in vaccinated and unvaccinated patients (standardized
incidence ratio, 0.99; 95% confidence interval, 0.29 to 3.43).
Conclusions: Use of the zoster vaccine was uncommon among older patients with autoimmune diseases,
including those not exposed to immunosuppressive medications. The short-term risk of HZ did not appear to be
increased in vaccinated patients, even among those using immunosuppressive therapies (for example, biologics) at
the time of vaccination. However, our study was limited by the small number of vaccinated patients, and further
evidence is needed to confirm the vaccine’s safety and efficacy in this population.
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Herpes zoster (HZ) infection, also known as shingles, is
caused by the reactivation of latent varicella-zoster virus
(VZV) and usually occurs decades after primary infec-
tion. HZ is characterized by a painful blistering rash and
occurs mostly in older adults. Many patients experience
persistent pain after the rash heals, a common yet debil-
itating complication known as postherpetic neuralgia
(PHN) [1,2]. In the United States, the age- and sex-
adjusted incidence rate (IR) of HZ is estimated to be 3.0
to 4.0 per 1,000 person-years [3-5]. Older age is the
most important risk factor for the development of both
HZ and PHN [3,4]. Disease risk is elevated in individuals
who are immune-suppressed due to human immunode-
ficiency virus (HIV) infection and transplantation [3,4,6].
Recent studies reported an increased risk of HZ in
patients with rheumatoid arthritis (RA) that is attributa-
ble both to the disease and to treatment with anti-
tumor necrosis factor alpha (anti-TNF) therapies and
other immunosuppressive agents [7,8]. In addition, anti-
TNF therapies has been associated with a more severe
course of HZ among patients with rheumatic diseases;
those receiving anti-TNF therapies were 9 times more
likely than those not to be hospitalized for HZ [9].
Zostavax, a live attenuated vaccine, was approved in
2006 for use in individuals 60 years of age or older to
reduce the risk and severity of HZ. The Advisory Commit-
tee on Immunization Practices (ACIP) recommended that
all adults older than 60 years be considered for vaccina-
tion, with certain exceptions [10]. Along with patients
with certain malignancies and HIV/AIDS, patients receiv-
ing biologic agents such as anti-TNF therapies, some non-
biologic disease-modifying antirheumatic drugs
(DMARDs), such as high doses of methotrexate, and high
doses of glucocorticoids were also excluded. The concern
is that zoster vaccine, a live vaccine, could acutely trigger
the development of HZ in patients with compromised
immune systems in a short time frame (for example,
within 4 to 6 weeks after vaccination) despite conferring a
longer-term protection against the development of HZ.
Based on expert opinion, glucocorticoids at prednisone-
equivalent doses up to 20 mg/day, low-doses of metho-
trexate (< 0.4 mg/kg/week, a typical dose for patients with
autoimmune diseases), azathioprine (< 3.0 mg/kg/day),
and 6-mercaptopurine (< 1.5 mg/kg/day) were considered
acceptably safe so as not to require a contraindication for
use of zoster vaccine. Similarly, the American College of
Rheumatology (ACR) 2008 guidelines for the use of biolo-
gic and nonbiologic DMARDS did not recommend the
administration of zoster vaccine to patients with RA or
other rheumatic diseases treated with biologics [11].
In light of the uncertainties regarding the use, safety,
and effectiveness of zoster vaccine in this population, we
used the administrative claims data of a large nation-
wide health plan to investigate the following aims in a
cohort of patients diagnosed with RA, psoriatic arthritis,
psoriasis, ankylosing spondylitis, and/or inflammatory
bowel diseases: (a) to describe the use of zoster vaccina-
tion over time; (b) to determine the extent to which zos-
ter vaccine was used in patients taking concomitant
immunosuppressive agents; (c) to assess patient charac-
teristics associated with receipt of zoster vaccine; and
(d) to evaluate the incidence of HZ in patients who
received and did not receive zoster vaccine.
Materials and methods
Study population
We conducted a retrospective cohort study by using
administrative claims data from Aetna, a nationwide
health plan that provides medical coverage to more than
17 million individuals in the United States, from January
1, 2006, to August 31, 2009. The cohort included
patients with RA, psoriatic arthritis, psoriasis, ankylosing
spondylitis, and inflammatory bowel diseases, identified
by using the International Classification of Diseases, 9th
revision (ICD-9) and National Drug Codes (NDC)
codes. Patients were included if there were (a) two ICD-
9 diagnosis codes from an outpatient physician or hospi-
tal encounter, separated by at least 7 days and occurring
within 365 days; or (b) one physician- or hospital-
encounter diagnosis code followed by a prescription for
medications used to treat autoimmune diseases within
365 days (diagnosis codes and medications listed in
Additional file 1). We defined each subject’si n d e xd a t e
(patients consist of a mix of incident and prevalent
cases) as the date of the second diagnosis code or the
date when the prescription was filled. Patients who met
definitions for two or more of the diseases of interest
were categorized into a multiple diseases category, and
their index date was defined as the earliest of all dis-
ease-specific index dates.
To ensure that we had complete medical and phar-
macy claims necessary to identify and characterize the
study population, all subjects were required to have a
“baseline period” of at least 183 continuous days during
which they had medical and pharmacy benefits; subjects
aged 65 or older had to be enrolled in a Medicare
Advantage plan with a concomitant pharmacy benefit
administered by Aetna. Follow-up started on the later of
t h ei n d e xd a t eo rt h ed a t eo nw h i c ht h es u b j e c th a da
baseline period of at least 183 days. Subjects were cen-
sored when they lost either medical or pharmacy bene-
fits, died, or for individuals aged 65 years or older, if
Aetna became the secondary payer to Medicare. Patients
were excluded if they were younger than 50 years at the
start of follow-up or received zoster vaccine during the
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use of zoster vaccine in immune-competent individuals
aged 60 years or older [10], given the increased HZ risk
previously observed in this population, we included
those between 50 and 60 years of age in our analysis to
assess the extent to which zoster vaccine was used.
Assessment of vaccination status, HZ infection, and
exposure to immunosuppressive agents
Zoster vaccine was covered under the health plan’s
medical benefit for individuals aged 60 or older begin-
ning June 1, 2006, and was ascertained by using the
Current Procedural Terminology (CPT) code 90736.
Reimbursement of zoster vaccine for patients younger
than 60 years was made on a case-by-case basis. Cases
of HZ were identified by the first HZ claim for each
patient that was preceded or followed by a prescription
for acyclovir, famciclovir, and valacyclovir within 30
days of the HZ claim date. Exposures to immunosup-
pressive agents were ascertained by the days’ supply for
all relevant medications. To estimate cumulative gluco-
corticoid exposure as a time-varying variable, cumulative
average daily doses were calculated by summing the
total amount of oral glucocorticoids prescribed in the
preceding 6 months and then dividing the total amount
by 183 days. Subjects were then categorized into four
groups based on their cumulative average daily predni-
sone-equivalent glucocorticoid dose: none, low (less
than 10 mg/day), medium (10 to 20 mg/day), and high
(greater than 20 mg/day).
Statistical analyses
To characterize use of the zoster vaccination (Aim 1),
we calculated the incidence proportion of zoster vacci-
nation for each 6-month interval beginning July 1, 2006,
and ending August 31, 2009. For each time interval, the
denominator was the number of subjects who were
unvaccinated at the start of the interval and were under
observation throughout the entire interval, and the
numerator was the number of these subjects who were
vaccinated during the interval. Because we had claims
up to August 31, 2009, the incidence proportion from
July 1, 2009, to August 31, 2009, was multiplied by 3 to
approximate the incidence proportion for the 6-month
period ending December 31, 2009.
To characterize the immune status of patients at time
of vaccination (Aim 2), we described the numbers and
percentages of patients who used anti-TNF therapies
(etanercept, infliximab, adalimumab), other biologic
agents (abatacept, rituximab), traditional DMARDs
(methotrexate, hydroxychloroquine, sulfasalazine,
azathioprine, leflunomide, mercaptopurine), and oral
glucocorticoids 30 days before and up to 30 days after
the administration of zoster vaccine. These analyses
were conducted in patients who received zoster vaccine
and were followed up for at least 30 days after
vaccination.
For Aim 3, we used Cox proportional hazards regres-
sion models to assess patient characteristics associated
with time to HZ vaccination. Subject characteristics
examined were gender, type of autoimmune disease, and
several time-varying factors including age, co-morbid-
ities measured by using the Charlson co-morbidity
index [12], number of physician visits, hospitalization
(yes or no), history of HZ infection (recent, within the
past 6 months; remote, more than 6 months ago), his-
tory of influenza and pneumococcal vaccine (within the
past 12 months), and use of medications listed in Aim
2. Whenever an event occurred, the time-varying char-
acteristics of interest were ascertained as of that time
for all patients by using claims in the preceding 6-
months period, unless otherwise specified.
For Aim 4, accrual of person-time began at the start
of follow-up, and a vaccinated subject would contribute
both unvaccinated and vaccinated person-time. We cal-
culated the crude and age- and sex-specific incidence
rates of HZ in vaccinated and unvaccinated person-
times. We applied the age- and sex-specific incidence
rates of the unvaccinated to age- and sex-specific vacci-
nated person-time to derive the expected number of HZ
cases among the vaccinated and calculated the standar-
dized incidence-rate ratio as the observed divided by the
expected number of cases [13].
Sensitivity analyses
Because zoster vaccine was approved for use in the Uni-
ted States in May 2006 in individuals aged 60 or older,
sensitivity analyses were conducted (a) in patients for
whom we had complete medical and pharmacy claims
prior to or since June 1, 2006, to avoid misclassification
of vaccination status in patients who might have been
vaccinated before joining the health plan; and (b) in
patients aged 60 or older as of the start of follow-up.
B e c a u s eH Zi n f e c t i o n sd i a g n o s e dl a t ei nt h ec o u r s eo f
the infection might not benefit from or receive antiviral
medications, and approximately 10% to 20% of HZ cases
were not treated with antiviral medication, we con-
ducted a sensitivity analysis that used an alternate defi-
nition for HZ that required only the HZ diagnosis code
to calculate incidences of HZ in vaccinated and unvacci-
nated patients.
The University of Alabama at Birmingham Institu-
tional Review Board approved the study and waiver of
informed consent.
Results
We identified 44,115 eligible subjects classified as having
at least one of the autoimmune diseases of interest who
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baseline, their average age was 58.1 (standard deviation
(SD), 6.7) years and 27,443 (62.2%) were female; 19,326
(43.8%) had RA, 867 (2.0%) had psoriatic arthritis (PsA),
10,712 (24.3%) had psoriasis (PsO), 633 (1.4%) had AS,
8,639 (19.6%) had IBD, and 3,938 (8.9%) had two or
more of these diseases. During follow-up, 551 (1.2%)
subjects received zoster vaccine. The earliest claim for
vaccination occurred in August 2006; subsequently, vac-
cine use increased continuously over time (Figure 1).
The distribution of patients’ characteristics at baseline
by vaccination status is presented in Table 1.
Among the 551 subjects who received zoster vaccine,
complete claims history for at least 30 days after vacci-
nation was available for 514 subjects. At the time of vac-
cination, 32 (6.2%) subjects were using anti-TNF
therapy, 34 (6.6%) were using methotrexate, and 33
(6.4%) were using oral glucocorticoids (Table 2). In the
30 days after vaccination, 40 (7.8%) subjects used anti-
TNF therapy, 45 (8.8%) used methotrexate, and 48
(9.3%) used oral glucocorticoids. A total of 47 patients
used biologics at some time within 30 days before and
after vaccination. None of the 47 subjects developed HZ
in the 30 days after vaccination. Their average age was
60 years (standard deviation, 5); 64% were women; and
70% were not exposed to oral glucocorticoids, 28% to a
daily average dose of no more than 20 mg, and 2% to a
daily average dose of 20 mg or more.
Patients using anti-TNF therapies were less likely to
receive zoster vaccine than those who were not using
anti-TNF agents (hazard ratio (HR), 0.47; 95% CI, 0.33
to 0.67) (Table 3). Patients who were using other biolo-
gics (HR, 0.52; 95% CI, 0.19 to 1.40) or high-dose oral
glucocorticoids (HR, 0.46; 95% CI, 0.15 to 1.45) were
only half as likely as were non-users to receive zoster
vaccine, but these associations did not reach statistical
significance. Patients aged 60 to 64 years were most
likely to receive zoster vaccine; those with fewer co-
morbidities and those without hospitalization within the
past 6 months were more likely to receive zoster
Figure 1 Incidence proportion for each 6-month period of zoster vaccination by calendar year from June 1, 2006, to December 31,
2009. The proportion is expressed as the proportion of unvaccinated individuals under observation and vaccinated in each 6-month period. It
does not include individuals vaccinated in previous time periods.
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HZ were more likely to be vaccinated. Finally, patients
who had more physician visits in outpatient settings and
those who had received influenza or pneumococcal vac-
cine in the past year were more likely to be vaccinated.
Results of the analysis that was restricted to individuals
aged 60 years or older were similar to the main results
(Table 3). A majority (> 80%) of the patients received
their vaccine from family practice or internal medicine
physicians, with less than 5% from dermatologists,
gastroenterologists, or rheumatologists, both in the over-
all cohort and in patients who were exposed to biologics
at the time of vaccination.
During 88,354 observed person-years, 761 cases of HZ
occurred (incidence rate (IR), 8.6 per 1,000 person-
years). The IR increased with age from 8.14 per 1,000
person-years among those aged 50 to 54 years to 15.30
per 1,000 person-years among those 90 years or older.
Five cases of HZ occurred during vaccinated person-
time (crude IR, 9.97 per 1,000 person-years), and 756
HR occurred during unvaccinated person-time (crude
IR, 8.61 per 1,000 person-years). The age- and sex-stan-
dardized IR (expected IR) for the vaccinated was 10.06
per 1,000 person-years, resulting in a standardized IR
ratio (vaccinated to unvaccinated) of 0.99 (95% CI, 0.29
to 3.43).
The five cases of HZ in the vaccinated patients
occurred 7, 131, 201, 214, and 667 days after vaccina-
tion. Within 90 days before vaccination, the only filled
prescription for an immunosuppressive agent for the
patient who developed HZ on day 7 after vaccination
was for a 15-day supply of prednisone approximately 2
months before receipt of zoster vaccination. None of the
five patients was hospitalized.
Results from sensitivity analyses restricted to indivi-
duals under observation continuously from the time zos-
ter vaccine was approved in 2006 had similar results
(data not shown). When requiring only an HZ diagnosis
code, the result was consistent, in that the crude inci-
dence rates were the same between vaccinated (14.4 per
1,000 person-years) and unvaccinated (13.1 per 1,000
person-years) patients. With Poisson regression, the
incidence rate ratio was 0.99 (95% CI, 0.35 to 2.82).
Discussion
In this large prospective cohort study of more than
40,000 patients with autoimmune diseases, we showed
that despite their increased risk of developing HZ, only
551 (1.2%) received zoster vaccine. We also showed that
approximately 6% of those who received the vaccine
were currently using anti-TNF therapies, and none
developed HZ within 1 month after vaccination.
The administration of zoster vaccine in patients
exposed to biologics is in conflict with recommenda-
tions from ACIP and ACR. More than 80% of the vacci-
nated patients received their vaccine from their primary
care physicians; it is possible that they may not be
aware of their patients’ exposure to immunosuppressive
agents or the contraindication. In patients with
immune-mediated inflammatory diseases who receive
targeted immunosuppressive therapies (for example,
anti-TNF therapy), it is currently not known whether
the benefits of zoster vaccine outweigh any theoretic
safety concerns, and many experts have called for
Table 1 Baseline patient characteristics by vaccination
status
Vaccination status
Baseline characteristics, n (%) Vaccinated
n = 551
Unvaccinated
n = 43,564
Age groups (years)
50 to 59 202 (36.7) 30,156 (69.2)
60 to 64 275 (49.9) 9,573 (22.0)
65 and older 74 (13.4) 3,835 (8.8)
Women 352 (63.9) 27,091 (62.2)
Inflammatory/Autoimmune disease
RA 206 (37.4) 19,120 (43.9)
Psoriatic arthritis 11 (2.0) 856 (2.0)
Psoriasis 146 (26.5) 10,566 (24.3)
Inflammatory bowel diseases 136 (24.7) 8,503 (19.5)
Ankylosing spondylitis 8 (1.5) 625 (1.4)
Multiple diseases 44 (8.0) 3,894 (8.9)
Medications
a
TNF antagonists user 27 (4.9) 4,186 (9.6)
Other biologics user 0 (0) 198 (0.5)
Conventional DMARDs user 92 (16.7) 9,312 (21.4)
Oral glucocorticoids
b
None 456 (82.8) 34,267 (78.7)
Low 86 (15.6) 8,041 (18.5)
Medium 7 (1.3) 902 (2.1)
High 2 (0.4) 354 (0.8)
Charlson comorbidity index
0 287 (52.1) 19,971 (45.8)
1 181 (32.9) 16,565 (38.0)
≥ 2 83 (15.1) 7,028 (16.1)
Inpatient hospitalization
No 466 (84.6) 36,158 (83.0)
Yes 45 (15.4) 7,406 (17.0)
Number of outpatient physician visits
0-2 83 (15.1) 8,705 (20.0)
3-5 227 (41.2) 16,843 (38.7)
6-10 185 (33.6) 13,376 (30.7)
11 and more 54 (9.8) 4,642 (10.7)
DMARDS, Disease-modifying antirheumatic drugs; RA, rheumatoid arthritis;
TNF, tumor necrosis factor.
aMeasured in the 6-month baseline period before
the start of observation
bCumulative average daily prednisone-equivalent glucocorticoid dose in the
past 183 days: none, low (< 10 mg/day), medium (10-20 mg/day), and high (>
20 mg/day).
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vaccine in this patient population [14,15]. In pediatric
HIV patients, varicella vaccine has been administered
safely in children with or without primary varicella
infection [16,17] and is highly effective in preventing
varicella infection and subsequent HZ [18]. Moreover,
yellow-fever vaccine, another live attenuated vaccine,
was administered to 17 RA patients who were previously
immunized and were currently receiving infliximab;
none reported yellow-fever related symptoms after vac-
cination [19].
In our study, among 551 vaccinated subjects, HZ devel-
oped in five after vaccination; none was hospitalized, and
one occurred within 1 month of vaccination. Of interest,
the patient in whom HZ developed within 1 month after
vaccination was not exposed to biologics, glucocorticoids,
or traditional DMARDs at time of vaccination. In the Shin-
gles Prevention Study, seven confirmed cases of HZ
occurred within 42 days after vaccination among 19,270
vaccinated subjects [20]. We observed only one such case
among 551 vaccinated patients with autoimmune diseases.
Taken together, our result suggests that a short-term
increase in the risk of infection might not exist, as might be
feared with a live-virus vaccine. However, although our
results did not raise any safety concern, it is important to
note that the administration of zoster vaccine to these indi-
viduals was selective. Subjects who took biologics and high
doses of oral glucocorticoids were less likely to be immu-
nized, whereas younger and healthier patients were more
likely to be vaccinated. Our study suggested that zoster vac-
cine can be administered safely to a selected subgroup of
patients with the autoimmune diseases studied but did not
provide definitive evidence that it is safe for all.
In considering the effectiveness of the zoster vaccine
in this population, we did not find any difference in the
incidence rates of HZ among the vaccinated and the
unvaccinated patients. However, this and other findings
must be interpreted in light of the study’ limitations.
The most important limitation is the small number of
patients who received zoster vaccine (n = 551) and the
even fewer in whom HZ developed after vaccination (n
= 5). As a result, the overall IRs, and especially the age-
and sex-specific IRs, were not so reliable. Coupled with
a selection bias that those who were vaccinated were
younger, healthier, and less likely to be immune sup-
pressed, no conclusion could be drawn from the finding
that incidence rates of HZ in vaccinated and unvacci-
nated patients were comparable. Misclassification of
immunosuppressive agent use might have occurred if
patients filled prescriptions from a pharmacy, but they
were verbally told by their healthcare provider to dis-
continue the medications temporarily before vaccination.
Another limitation of the study is that we lacked medi-
cal records to confirm or evaluate the severity of HZ
cases identified by using the claims data. Finally, we did
not have information on race/ethnicity, a factor that has
been associated with risk of HZ [21].
The underuse of zoster vaccine concerns not only
patients with contraindications but also those who had
no contraindication to the use of zoster vaccine. One of
the barriers is likely provider concern about inadvertent
administration of the vaccine to immune-suppressed
patients [22]. Another possible reason is the lack of
information on the efficacy and safety of zoster vaccine
in these patients, who were not included in vaccine clin-
ical trials. In addition, we found that older patients were
Table 2 Biologic and nonbiologic DMARDs use 30 days before and after zoster vaccination (n = 514)
30 days before vaccination Day of vaccination 30 days after vaccination
n % n % n %
Anti-TNF 40 7.8 32 6.2 40 7.8
Etanercept 18 3.5 12 2.3 18 3.5
Adalimumab 11 2.1 9 1.8 11 2.1
Infliximab 11 2.1 11 2.1 11 2.1
Other biologics
a 4 0.8 4 0.8 4 0.8
Nonbiologic DMARDs
Methotrexate 52 10.1 34 6.6 45 8.8
Sulfasalazine 16 3.1 13 2.5 16 3.1
Hydroxychloroquine 26 5.1 17 3.3 25 4.9
Azathioprine 1 0.2 1 0.2 1 0.2
Leflunomide 3 0.6 3 0.6 3 0.6
Cyclosporine 7 1.4 6 1.2 7 1.4
6-Mercaptopurine 5 1.0 3 0.6 5 1.0
Oral glucocorticoid 45 8.8 33 6.4 48 9.3
DMARDS, Disease-modifying antirheumatic drugs; RA, rheumatoid arthritis; TNF, tumor necrosis factor.
aThe categories (columns) are not exclusive (for example, a
patient who used anti-TNF therapies continuously during the 60-day period would be counted in all three categories).
bAbatacept, rituximab.
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recommendations supporting its use among individuals
older than 60 years. This finding is consistent with
those from previous studies that showed immunization
lagging in older adults [23] and raises a serious concern
because zoster vaccine appears to be underused in the
population with the highest disease risk. A number of
barriers to the use of zoster vaccine have been
identified, with the most important being financial con-
cerns, reimbursement issues, and storage difficulties
[22]. In our study, zoster vaccine use increased continu-
ously since it was approved in 2006. This points to
another potential barrier to the use of the zoster vaccine
(the newness of the vaccine) and suggests that programs
educating primary care physicians and specialists may
help to increase the appropriate vaccine use. As
Table 3 Fixed and time-varying
a patient characteristics associated with vaccination
All subjects Subjects aged 60 years or older
b
Baseline Hazard ratio 95% Confidence interval Hazard ratio 95% Confidence interval
Age groups, years
50-59 0.06 0.05-0.08 NA NA
60-64
c 1.00 -- -
≥ 65 0.41 0.31-0.53 0.42 0.33-0.54
Women, n (%) 1.13 0.95-1.35 1.17 0.97-1.41
Disease status
Rheumatoid arthritis
d 1.00 -- -
Psoriatic arthritis 1.58 0.86-2.91 1.27 0.63-2.59
Psoriasis 1.48 1.17-1.86 1.54 1.21-1.95
Inflammatory bowel diseases 1.71 1.36-2.14 1.64 1.29-2.09
Ankylosing spondylitis 1.45 0.71-2.97 1.23 0.54-2.79
Multiple diseases 1.00 0.72-1.39 1.01 0.71-1.43
History of herpes zoster infection
None
e 1.00 -- -
Recent 2.84 1.34-6.01 2.21 0.91-5.35
Remote 0.93 0.51-1.69 0.82 0.42-1.59
Medications (current use)
TNF antagonists 0.47 0.33-0.67 0.41 0.27-0.61
Other biologics (see Additional file 1) 0.52 0.19-1.40 0.59 0.22-1.58
Conventional DMARDs 0.92 0.72-1.19 0.91 0.70-1.19
Oral glucocorticoids
None
f 1.00 -- -
Low/medium 0.84 0.66-1.08 0.85 0.66-1.10
High 0.46 0.15-1.45 0.53 0.17-1.68
Charlson co-morbidity index
0
g 1.00 -- -
1 0.76 0.61-0.95 0.77 0.61-0.97
≥ 2 0.57 0.42-0.78 0.57 0.42-0.79
One or more inpatient physician visit 0.53 0.40-0.72 0.50 0.37-0.69
Number of outpatient physician visits
0-2
h 1.00 -- -
3-5 1.68 1.32-2.14 1.70 1.31-2.19
6-10 1.80 1.39-2.34 1.80 1.37-2.38
>1 0 2.08 1.47-2.93 2.03 1.41-2.92
Influenza vaccine in the past year 2.25 1.87-2.71 2.05 1.69-2.49
Pneumococcal vaccine in the past year 1.79 1.45-2.21 1.81 1.45-2.26
aGender and disease status were fixed; all other characteristics were time-varying. Time-varying characteristics were ascertained by using claims in the preceding
6-month period, unless otherwise specified in the table.
bSensitivity analysis restricted to individuals aged 60 and older.
Reference groups were as follows:
cage category 60-64;
dRA patients;
eSubjects without prior zoster infection;
fsubjects not prescribed oral glucocorticoids in the
past 6 months (cumulative average daily prednisone-equivalent glucocorticoid dose: low/medium ≤20 mg/day and high (> 20 mg/day);
gsubjects with Charlson
score = 0;
hsubject who had none to two outpatient physician encounter (s) in the past 6 months. DMARDS, disease-modifying antirheumatic drugs; RA,
rheumatoid arthritis; TNF, tumor necrosis factor. Bolded data indicates statistically significant associations.
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Page 7 of 9expected, more frequent physician contact and receipt of
other vaccinations, including influenza or pneumococcal
vaccine, was associated with a greater likelihood of
receiving zoster vaccine. These associations may reflect
physician attentiveness and patients’ health-seeking
behaviors.
Conclusions
Zoster vaccine was underused in patients with autoim-
mune diseases despite their increased risk of developing
HZ. Contrary to clinical guidelines, a small number of
patients receiving anti-TNF therapies were vaccinated,
and none developed zoster infection within 30 days after
vaccination. The incidence rates of HZ were similar in
the vaccinated and unvaccinated person-times. The
results regarding safety and effectiveness are preliminary,
and future evaluations are needed to understand better
the risks and benefits associated with zoster vaccine in
patients with autoimmune disease and to help refine
guidelines for the use of zoster vaccine.
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